Chris Whitmore, CPA
Chief Financial Officer
As chief financial officer, Mr. Whitmore is responsible for leading Immune-Onc’s financial strategy, planning and operations. These activities include fundraising, investor relations, financial management, budgeting, forecasting, treasury, tax, accounting operations, reporting and compliance, and administrative operations.
Mr. Whitmore is a highly accomplished financial executive who brings more than 20 years of experience in strategic finance, accounting, operations, investor relations, and organizational development. Mr. Whitmore has held management positions within the biotech industry ranging from pre-IND development-stage organizations to commercial enterprises and has deep experience in capital raising via private and public financings, including IPOs, venture and convertible debt, in-licensing partnerships, royalty monetization and grant funding.
He joins Immune-Onc from Notable Labs, where he served as chief financial officer since 2021. Prior to Notable Labs, he served as vice president of finance and administration, and secretary, for Harpoon Therapeutics, a publicly traded oncology company. During his tenure, he supported the company’s crossover financing, initial public offering (IPO), follow-on financings, licensing and collaborative arrangements with AbbVie, and public company operations. Prior to Harpoon, he held management positions at Immune Design (acquired by Merck), AcelRx Pharmaceuticals, and Sangamo Therapeutics. He started his career at KPMG LLP, where he served in the audit practice. He received his B.A. in Business Economics from the University of California, Santa Barbara and holds an active CPA license.